Recent Publications
Zhang Y, Tuzova M, Xiao ZX, Cruikshank WW, Center DM.
J Immunol. 2008 Jan 1;180(1):402-408;
Croq F, Vizioli J, Tuzova M, Tahtouh M, Sautiere PE, Van Camp C, Salzet M, Cruikshank WW, Pestel J, Lefebvre C.
Glia. 2010 Nov 1;58(14):1649-1662;
3. Interleukin-16 as a marker of Sézary syndrome onset and stage.
Richmond J, Tuzova M, Parks A, Adams N, Martin E, Tawa M, Morrison L, Chaney K, Kupper TS, Curiel-Lewandrowski C, Cruikshank W.
J Clin Immunol. 2011 Feb;31(1):39-50;
4. Loss of nuclear pro-IL-16 facilitates cell cycle progression in human cutaneous T cell lymphoma.
Curiel-Lewandrowski C, Yamasaki H, Si CP, Jin X, Zhang Y, Richmond J, Tuzova M, Wilson K, Sullivan B, Jones D, Ryzhenko N, Little F, Kupper TS, Center DM, Cruikshank WW.
J Clin Invest. 2011 Dec;121(12):4838-4849;
5. Introduction of pro-interleukin-16 inhibits T-lymphoblastic leukemia growth in mice.
Richmond J, Finkel M, Studwell A, Little F, Cruikshank W.
J Cancer Res Clin Oncol. 2011 Oct;137(10):1581-1585;
6. Preferential migration of T regulatory cells induced by IL-16.
McFadden C, Morgan R, Rahangdale S, Green D, Yamasaki H, Center D, Cruikshank W.
J Immunol. 2007 Nov 15;179(10):6439-6445;
Morgan RK, McAllister B, Cross L, Green DS, Kornfeld H, Center DM, Cruikshank WW.
J Immunol. 2007 Jun 15;178(12):8081-8089;
Meagher C, Beilke J, Arreaza G, Mi QS, Chen W, Salojin K, Horst N, Cruikshank WW, Delovitch TL.
Diabetes. 2010 Nov;59(11):2862-1271;
Matsumoto Y, Fujita T, Hirai I, Sahara H, Torigoe T, Ezoe K, Saito T, Cruikshank WW, Yotsuyanagi T, Sato N.
Burns. 2009 May;35(3):383-389;
10. Regulation of cellular processes by interleukin-16 in homeostasis and cancer.
Richmond J, Tuzova M, Cruikshank W, Center D. J Cell Physiol. 2014 Feb;229(2):139-47. doi: 10.1002/jcp.24441. Review.
11. Marina Tuzova, Jillian Richmond, Deon Wolpowitz, Clara Curiel-Lewandrowski, Keri Chaney, Thomas Kupper, William Cruikshank
Leukemia & Lymphoma Accepted for publication: 1–28.
Posted online on 2 May 2014.
Read More: http://informahealthcare.com/toc/lal/0/ja